Laboratory and Instrumental Diagnostics

Bettocchi, Stefano; Murgia, Ferdinando; Greco, Francesca; Morena, Maria Grazia; Palieri, Tea; Pisante, Ambra; Fascilla, Fabiana Divina; Nappi, Luigi

doi:10.1007/978-3-031-11701-5_17

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main laboratory tests, which included complete blood count, clotting test, assessment of renal function, measurement of inflammatory and sepsis markers, and analysis of serum proteins and albumin, were performed at the Central Medical Laboratory of University Hospital “Policlinico Riuniti” of Foggia (Italy), following current laboratory methods, as described elsewhere [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study

Netti,

Soccio,

Catalano

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The immune system’s amplified response to SARS-CoV-2 may lead to the production of autoantibodies, but their specific impact on disease severity and outcome remains unclear. This study aims to assess if hospitalized COVID-19 patients face a worse prognosis based on ANA presence, even without autoimmune diseases. We performed a retrospective, single-center, observational cohort study, enrolling 638 COVID-19 patients hospitalized from April 2020 to March 2021 at Hospital “Policlinico Riuniti” of Foggia (Italy). COVID-19 patients with a positive ANA test exhibited a significantly lower 30-day survival rate (64.4% vs. 83.0%) and a higher likelihood of severe respiratory complications during hospitalization than those with negative ANA screening (35.4% vs. 17.0%) (p < 0.001). The association between poor prognosis and ANA status was identified by calculating the HALP score (Hemoglobin-Albumin-Lymphocyte-Platelet), which was lower in COVID-19 patients with a positive ANA test compared to ANA-negative patients (108.1 ± 7.4 vs. 218.6 ± 11.2 AU; p < 0.011). In detail, COVID-19 patients with a low HALP showed a lower 30-day survival rate (99.1% vs. 83.6% vs. 55.2% for high, medium, and low HALP, respectively; p < 0.001) and a higher incidence of adverse respiratory events compared to those with high and medium HALP (13.1% vs. 35.2% vs. 64.6% for high, medium, and low HALP, respectively; p < 0.001). In summary, ANA positivity in COVID-19 patients appears to be linked to a more aggressive disease phenotype with a reduced survival rate. Furthermore, we propose that the HALP score could serve as a valuable parameter to assess prognosis for COVID-19 patients.

show abstract

Section: Methodsmentioning

confidence: 99%